Health news
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linzagolix for the treatment of uterine fibroids. Linzagolix is a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. The NDA…
A New Drug Application (NDA) for linzagolix for the treatment of uterine fibroids has been submitted to the Food and Drug Administration. Linzagolix is a novel, oral gonadotropin-releasing hormone (GnRH) receptor antagonist. The NDA submission…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021